RUNX3 Downregulation in Human Lung Adenocarcinoma is Independent of p53, EGFR or KRAS Status

Pathology & Oncology Research

Bee Keow Peh¹  Min En Nga⁴  Mohd Feroz Mohd Omar³  Bhavin Thakkar²  Ross Soo¹  Yoshiaki Ito³  Manuel Salto-Tellez⁵  Kosei Ito⁷  Richie Soong¹  Tuty Muliana Ismail⁶ 

[1] Centre for Translational Medicine, National University of Singapore$$National University Hospital$$;Centre for Translational Medicine, National University of Singapore$$;Centre for Translational Medicine, National University of Singapore$$National University of Singapore$$;National University Hospital$$;Centre for Translational Medicine, National University of Singapore$$National University of Singapore$$Queen’s University Belfast$$;National University Hospital$$National University of Singapore$$;Nagasaki University Graduate School of Biomedical Science$$

关键词: RUNX3;   

DOI  :  10.1007/s12253-011-9485-5

学科分类：生理学与病理学

来源: Springer

【 摘 要 】

RUNX3 aberrations play a pivotal role in the oncogenesis of breast, gastric, colon, skin and lung tissues. The aim of this study was to characterize further the expression of RUNX3 in lung cancers. To achieve this, a lung cancer tissue microarray (TMA), frozen lung cancer tissues and lung cell lines were examined for RUNX3 expression by immunohistochemistry, while the TMA was also examined for EGFR and p53 expression. RUNX3 promoter methylation status, and EGFR and KRAS mutation status were also investigated. Inactivation of RUNX3 was observed in 70% of the adenocarcinoma samples, and this was associated with promoter hypermethylation but not biased to EGFR/KRAS mutations. Our results suggest a central role of RUNX3 downregulation in pulmonary adenocarcinoma, which may not be dependent of other established cancer-causing pathways and may have important diagnostic and screening implications.

【 授权许可】

Unknown